Design Therapeutics Inc (DSGN) FinancialsDSGNDesign Therapeutics Inc

Evaluating the bottom line, Design Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -34.13%, provide a clear picture of how effectively DSGN converts its operational activities into shareholder value.

In the context of the broader market, DSGN competes directly with industry leaders such as IVA and ATTO. With a market capitalization of $928.09M, it holds a significant position in the sector. When comparing efficiency, DSGN's gross margin of N/A stands against IVA's 100.00% and ATTO's N/A. Such benchmarking helps identify whether Design Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Design Therapeutics has shown a remarkable 1-year change of +163.70% and a year-to-date change of +66.04%, indicating a strong upward trend. The latest earnings report showed a GAAP EPS of -$0.32, beating expectations by $0.02, which may boost investor confidence.